ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1547

Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients

Anand Kumthekar1, Michail Alevizos2, Nicole Jordan3 and Anna R. Broder4, 1Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 2Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, 3Montefiore Medical Center, New York, NY, 4Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, lipids and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular
disease (CVD) is the leading cause of death among individuals with rheumatoid
arthritis (RA).  The 2010 EULAR guidelines recommend annual CV risk
assessment for all RA patients in accordance with national guidelines1. 
However, CVD risks are not being assessed frequently and systematically in RA
patients.  We implemented an Electronic Medical Record (EMR)-based
clinical decision support intervention at a large tertiary care center and
assessed the effects of this intervention on lipid screening among RA patients
by treating rheumatologists.  

Methods: We developed a
self-populated form that was incorporated into each EMR rheumatology visit and
contained the following information (Image):  1) dates of the latest
assessment of CVD risks (body mass index (BMI), blood pressure, smoking, lipid
screening); 2) the latest values for all of the above CVD risks; 3) Framingham
risk score calculator.  To evaluate the impact of this EMR-based
intervention, lipid screening rates among adult RA patients were compared pre
and post implementing this EMR tool.  LDL
levels were compared for patients seen, pre-intervention, 1/1/2012-6/30/2012 (2012),
and post-intervention, 1/1/2014-6/30/2014 (2014).  RA patients were
identified using a previously validated algorithm requiring two or more visits
with the ICD9 code 714.0 (Rheumatoid arthritis), and at least one
prescription for a disease modifying anti-rheumatic medication2. The
first visit within the study period was defined as the index visit. 
Wilcoxon-Mann-Whitney tests were used to compare continuous variables, and
Pearson’s Chi-square tests (or Fisher’s exact test when appropriate) were used
to compare categorical variables.

Results:   131 and 111 RA
patients seen in outpatient rheumatology clinics by rheumatologists in 2012 and
2014, respectively. Sex, race, and ethnicity were similar: 35% vs. 29% were
Black, 60% and 64% were Hispanic, 12% and 9% were men.
There were no age differences: mean (SD) 58(14) years old in 2012, and 59 (14)
years old in 2014. BMI was also similar: mean (SD) 30(7) kg/m2
 
in
2012, and 30(6) kg/m2
in 2014.  Lipid screening frequency in the subsequent 6 months was
32% in 2012 and 23% in 2014 (p=0.12). Median (SD) LDL was 96 (30) mg/dl in 2012,
and 109 (36) mg/dl in 2014 (p=0.09)

Conclusion:
Implementing an EMR based decision support tool did not improve rates of
screening for lipid abnormalities among RA patients.  Lipid screening
rates remained low.  Further studies are needed to identify and address
barriers to CVD screening in RA among rheumatologists and primary care
providers.

References:

1.Peters MJ, et al. Ann Rheum Dis.
2010 Feb; 69(2):325-331.

2. 
Kim SY, et al. Arthritis Res Ther. 2011 Feb 23;13(1):R32)   

Image: 
Decision support tool to aid rheumatologists with cardiovascular screening


Disclosure: A. Kumthekar, None; M. Alevizos, None; N. Jordan, None; A. R. Broder, Pfizer Inc, 2.

To cite this abstract in AMA style:

Kumthekar A, Alevizos M, Jordan N, Broder AR. Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/implementing-an-electronic-medical-recorded-based-clinical-decision-support-tool-did-not-improve-cardiovascular-risk-screening-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementing-an-electronic-medical-recorded-based-clinical-decision-support-tool-did-not-improve-cardiovascular-risk-screening-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology